Active Pharmaceutical Ingredients (API) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020

Transparency Market 

Research 

Active Pharmaceutical Ingredients (API) Market - Global 

Industry Analysis, Size, Share, Growth, Trends and 

Forecast 2014 - 2020 

Published Date 

2015-03-24 

137 Page Report 

Buy Now 

Request Sample 

Press Release 

Active Pharmaceutical Ingredients Market Expected to Reach USD 

185.9 billion Globally in 2020 

Transparency Market Research 

State Tower, 

90, State Street, Suite 700. 

Albany, NY 12207 

United States 

www.transparencymarketresearch.com 

sales@transparencymarketresearch.com

Active Pharmaceutical Ingredients 

(API) Market 

REPORT DESCRIPTION 

Active Pharmaceutical Ingredients (API) Market 

Size, Share, Growth, Trends and Forecast 2014 – 2020 

- Global Industry Analysis, 

According to a new market report published by Transparency Market Research "Active 

Pharmaceutical Ingredients (API) Market - Global Industry Analysis, Size, Share, Growth, Trends 

and Forecast 2014 - 2020," the global active pharmaceutical ingredients market was valued at 

USD 119.7 billion in 2013 and is anticipated to reach USD 185.9 billion by 2020, expanding at a 

CAGR of 6.5% during the forecast period from 2014 to 2020. 

According to the World Health Organization (WHO), in 2012, cancer was among the leading 

causes of morbidity and mortality worldwide, with approximately 14 million newly diagnosed 

cases and 8.2 million cancer-related deaths. Therefore, the oncology segment is expected to be 

fastest growing segment in the global API market. Moreover, most of the drugs in this segment 

contain High Potency Active Pharmaceutical Ingredients (HPAPIs) which itself is a rapidly growing 

segment in the global API market. The market growth of this segment will be particularly higher 

than other segments owing to loss of patent protection for blockbuster drugs such as Herceptin 

(Roche), Arimidex (AstraZeneca), Xeloda (Roche), Abraxane (Celgene), Temodar (Merck & Co.) 

and Vidaza (Celgene) between 2010 and 2014. 

Browse the full Active Pharmaceutical Ingredients (API) Market Report 

@ : 

http://www.transparencymarketresearch.com/active-pharmaceuticalingredients.html 

The global active pharmaceutical ingredients market is segmented on the basis of therapeutic 

area into non-steroidal anti-inflammatory drugs (NSAIDS), oncology drugs, anti-diabetic drugs, 

cardiovascular drugs, central nervous system drugs, musculoskeletal drugs, and others. The 

overall API market is expected to witness substantial growth during the forecast period from 


2



2014 to 2020, wherein oncology and central nervous system drugs segments would play a vital 

role. These segments are expected to grow at the highest CAGR during the forecast period from 

2014 to 2020. Cardiovascular drugs accounted for the largest market revenue share in 2013 due 

to the rising prevalence of cardiovascular diseases, sedentary lifestyle, and aging population. 

Bestselling products losing market exclusivity has been a common trend in all market segments, 

thus creating opportunities for generic products. This in turn increases the demand for APIs in 

particular therapeutics segments. 

Browse the full Active Pharmaceutical Ingredients (API) Market press 

release @ : 

http://www.transparencymarketresearch.com/pressrelease/activepharmaceutical-ingredients.htm 

Currently, biological drugs are gaining importance in the treatment of chronic diseases such as 

cancer and diabetes. These drugs are costlier due to challenging set of manufacturing 

requirements and difficult replication as against chemical APIs. Advancements in the production 

technology have enabled production of biosimilars that are not exact copies of innovator drugs, 

but highly comparable in terms of safety and efficacy. Europe has been the frontrunner in 

approving biosimilars, and the WHO has also set guidelines on similar lines of those set by the 

European Union. Regulatory pathways in the biosimilars space in different nations are evolving 

and this implies a great market opportunity ahead for the biopharmaceutical companies. 

Approval of the first biosimilar in the U.S. for filgrastim (2015) indicates opening up of the highly 

regulated U.S. market, which would further push the overall API market growth. 

Get Free Sample Report Active Pharmaceutical Ingredients (API) Market : 

http://www.transparencymarketresearch.com/sample/sample.php? 

flag=S&rep_id=1690 


3



Major players competing in this market include Boehringer Ingelheim Group, Cambrex 

Corporation, Dr. Reddy’s Laboratories, Ltd., BASF SE, Hospira, Inc., Lonza Group, Mylan, Inc., 

Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Actavis plc, and Wuxi Apptec. 

The global active pharmaceutical ingredients market is segmented as follows: 

Active Pharmaceutical Ingredients Market, by Type of Manufacturing 

Captive or In-house API manufacturing 

API contract manufacturing 

Active Pharmaceutical Ingredients Market, by Type of API 

Synthetic Chemical API 

Biological API 

Active Pharmaceutical Ingredients Market, by Type of Drug 

Branded or Innovative Prescription Drugs 

Generic Prescription Drugs 


4



Over-the-counter Drugs 

Active Pharmaceutical Ingredients Market, by Therapeutic Area 

Non-steroidal Anti-inflammatory Drugs (NSAIDs) 

Oncology Drugs 

Anti-diabetic Drugs 

Cardiovascular Drugs 

Central Nervous System Drugs 

Musculoskeletal Drugs 

Other Drugs (antibacterial, antiviral, antifungal, etc.) 

Active Pharmaceutical Ingredients Market, by Geography 

North America 


5



Europe 

Asia Pacific 

Rest of the World (RoW) 

TABLE OF CONTENT 

Chapter 1 Preface 

1.1 Report Description 

1.2 Market Segmentation 

1.3 Research Methodology 

1.3.1 Secondary Research 

1.3.2 Primary Research 

1.3.3 Assumptions 

1.4 List of Abbreviations 

Chapter 2 Executive Summary 

2.1 Market Snapshot: Global API Market (2013 & 2020) 

2.2 Comparative Analysis: Global API Market Revenue, by Geography, 2013 & 2020 (Value %) 


6



2.3 Global API Market Revenue, by Therapeutic Area, 2013 (USD Million) 

Chapter 3 Market Overview 

3.1 Introduction 

3.2 Market Dynamics 

3.2.1 Drivers 

3.2.1.1 Increase in Abbreviated New Drug Applications (ANDA) in the recent past boosted the 

demand for APIs 

3.2.1.2 Increase in Drug Master File (DMF) filing from Indian companies indicates a rapid API 

market growth 

3.2.2 Restraints 

3.2.2.1 Strict European Union regulatory policies restraining market growth 

3.2.3 Opportunities 

3.2.3.1 Patent expiry of lucrative biological drugs would provide new opportunities for specialized 

API manufacturers 

3.3 Event Impact Analysis 

3.4 Value Chain Analysis 

3.4.1 Global Active Pharmaceutical Ingredient Market: Value Chain Analysis 

3.5 Porter’s Five Forces Analysis: Global Active Pharmaceutical Ingredients Market 

3.5.1 Bargaining Power of Suppliers 

3.5.2 Bargaining Power of Buyers 


7



3.5.3 Threat of Substitutes 

3.5.4 Threat of New Entrants 

3.5.5 Competitive Rivalry 

3.6 Market Attractiveness Analysis: Global API Market, by Geography 

3.7 Competitive Landscape 

Chapter 4 Global Active Pharmaceutical Ingredients Market, by Types of Manufacturers 

4.1 Overview 

Million) 

4.1.1 Global Active Pharmaceutical Ingredients Market, by Type of Manufacturers, 2012 – 2020 (USD 

4.2 Captive or In-house API Manufacturing 

4.2.1 Global Captive or In-house API Manufacturing Market Revenue, 2012 – 2020 (USD Million) 

4.3 API Contract Manufacturing 

4.3.1 Global API Contract Manufacturing Market Revenue, 2012 – 2020 (USD Million) 

Chapter 5 Global Active Pharmaceutical Ingredients Market, by Type of API 

5.1 Synthetic Chemical API 

5.1.1 Differences between Small Molecule APIs and Biological APIs 

5.1.2 Global Synthetic Chemical API Market Revenue, 2012 – 2020 (USD Million) 

5.2 Biological API 


8



5.2.1 Top 10 drugs – Small Molecule vs. Biological, by API Type, 2008 and 2013 

5.2.2 Global Biological API Market Revenue, 2012 – 2020 (USD Million) 

Chapter 6 Global Active Pharmaceutical Ingredients Market, by Type of Drugs 

6.1 Branded or Innovative Prescription Drugs 

6.1.1 Global Branded or Innovative Prescription Drugs API Market Revenue, 2012 – 2020 (USD Million) 

6.2 Generic Prescription Drugs 

6.2.1 Global Generic Prescription Drugs API Market Revenue, 2012 – 2020 (USD Million) 

6.3 Over-the-counter (OTC) Drugs 

6.3.1 Global Over-the-counter (OTC) Drugs API Market Revenue, 2012 – 2020 (USD Million) 

Chapter 7 Global Active Pharmaceutical Ingredients Market, by Therapeutic Area 

7.1 Overview 

7.1.1 Global Active Pharmaceutical Ingredients Market, by Therapeutic Area, 2012 – 2020 (USD Million) 

7.2 Non-steroidal Anti-inflammatory Drugs 

7.2.1 Global NSAIDs API Market Revenue, 2012 – 2020 (USD Million) 

7.3 Oncology Drugs 

7.3.1 Global Oncology Drugs API Market Revenue, 2012 – 2020 (USD Million) 

7.4 Anti-diabetic Drugs 

7.4.1 Global Anti-diabetic Drugs API Market Revenue, 2012 – 2020 (USD Million) 


9



7.5 Cardiovascular Drugs 

7.5.1 Global Cardiovascular Drugs API Market Revenue, 2012 – 2020 (USD Million) 

7.6 Central Nervous System Drugs 

7.6.1 Global CNS Drugs API Market Revenue, 2012 – 2020 (USD Million) 

7.7 Musculoskeletal drugs 

7.7.1 Global Musculoskeletal Drugs API Market Revenue, 2012 – 2020 (USD Million) 

7.8 Other drugs (antibacterial, antiviral, antifungal, etc.) 

7.8.1 Global Other Drugs API Market Revenue, 2012 – 2020 (USD Million) 

Chapter 8 Global Active Pharmaceutical Ingredients Market, by Geography 

8.1 Overview 

8.1.1 Global Active Pharmaceutical Ingredients Market, by Geography, 2012 – 2020 (USD Million) 

8.2 North America 

8.2.1 North America API Market Revenue, 2012 – 2020 (USD Million) 

8.3 Europe 

8.3.1 Europe API Market Revenue, 2012 – 2020 (USD Million) 

8.4 Asia Pacific 

8.4.1 Asia Pacific API Market Revenue, 2012 – 2020 (USD Million) 

8.5 Rest of the World 

8.5.1 Rest of the World API Market Revenue, 2012 – 2020 (USD Million) 


10



Chapter 9 Global Market Analysis of Select NSAIDs, by Geography 

9.1 Paracetamol 

9.1.1 North America 

9.1.1.1 Demand and Consumption Analysis 

9.1.1.2 North America Paracetamol (APAP) Market Revenue, 2012 – 2020 (USD Million) 

9.1.1.3 North America Paracetamol (APAP) Market Volume, 2012 – 2020 (Metric Tons) 

9.1.2 Europe 


9.1.2.2 Europe Paracetamol (APAP) Market Revenue, 2012 – 2020 (USD Million) 

9.1.2.3 Europe Paracetamol (APAP) Market Volume, 2012 – 2020 (Metric Tons) 

9.1.3 Asia Pacific 


9.1.3.2 Asia Pacific Paracetamol (APAP) Market Revenue, 2012 – 2020 (USD Million) 

9.1.3.3 Asia Pacific Paracetamol (APAP) Market Volume, 2012 – 2020 (Metric Tons) 

9.1.4 Rest of the World 

9.1.4.1 Rest of the World Paracetamol (APAP) Market Revenue, 2012 – 2020 (USD Million) 

9.1.4.2 Rest of the World Paracetamol (APAP) Market Volume, 2012 – 2020 (Metric Tons) 

9.2 Ibuprofen 



11




9.2.1.2 North America Ibuprofen Market Revenue, 2012 – 2020 (USD Million) 

9.2.1.3 North America Ibuprofen Market Volume, 2012 – 2020 (Metric Tons) 

9.2.2 Europe 


9.2.2.2 Europe Ibuprofen Market Revenue, 2012 – 2020 (USD Million) 

9.2.2.3 Europe Ibuprofen Market Volume, 2012 – 2020 (Metric Tons) 



9.2.3.2 Asia Pacific Ibuprofen Market Revenue, 2012 – 2020 (USD Million) 

9.2.3.3 Asia Pacific Ibuprofen Market Volume, 2012 – 2020 (Metric Tons) 


9.2.4.1 Rest of the World Ibuprofen Market Revenue, 2012 – 2020 (USD Million) 

9.2.4.2 Rest of the World Ibuprofen Market Volume, 2012 – 2020 (Metric Tons) 

9.3 Aspirin 



9.3.1.2 North America Aspirin Market Revenue, 2012 – 2020 (USD Million) 

9.3.1.3 North America Aspirin Market Volume, 2012 – 2020 (Metric Tons) 

9.3.2 Europe 


12




9.3.2.2 Europe Aspirin Market Revenue, 2012 – 2020 (USD Million) 

9.3.2.3 Europe Aspirin Market Volume, 2012 – 2020 (Metric Tons) 



9.3.3.2 Asia Pacific Aspirin Market Revenue, 2012 – 2020 (USD Million) 

9.3.3.3 Asia Pacific Aspirin Market Volume, 2012 – 2020 (Metric Tons) 


9.3.4.1 Rest of the World Aspirin Market Revenue, 2012 – 2020 (USD Million) 

9.3.4.2 Rest of the World Aspirin Market Volume, 2012 – 2020 (Metric Tons) 

9.4 Naproxen 



9.4.1.2 North America Naproxen Market Revenue, 2012 – 2020 (USD Million) 

9.4.1.3 North America Naproxen Market Volume, 2012 – 2020 (Metric Tons) 

9.4.2 Europe 


9.4.2.2 Europe Naproxen Market Revenue, 2012 – 2020 (USD Million) 

9.4.2.3 Europe Naproxen Market Volume, 2012 – 2020 (Metric Tons) 



13




9.4.3.2 Asia Pacific Naproxen Market Revenue, 2012 – 2020 (USD Million) 

9.4.3.3 Asia Pacific Naproxen Market Volume, 2012 – 2020 (Metric Tons) 


9.4.4.1 Rest of the World Naproxen Market Revenue, 2012 – 2020 (USD Million) 

9.4.4.2 Rest of the World Naproxen Market Volume, 2012 – 2020 (Metric Tons) 

Chapter 10 Recommendations 

10.1 Enhance manufacturing capacity through acquisitions in targeted geographies 

10.2 Achieve cost leadership in specific API molecules 

Chapter 11 Company Profiles 

11.1 Actavis plc 

11.1.1 Company Overview 

11.1.2 Financial Overview 

11.1.3 Business Strategies 

11.1.4 Recent Developments 

11.2 BASF SE 




14




11.2.4 Recent developments 

11.3 Boehringer Ingelheim Group 





11.4 Cambrex Corporation 





11.5 Dr. Reddy’s Laboratories Ltd. 





11.6 Hospira, Inc. 




15





11.7 Lonza Group 





11.8 Mylan, Inc. 





11.9 Novartis International AG 





11.10 Pfizer, Inc. 




16



11.10.3 Product Portfolio 



11.11 Teva Pharmaceutical Industries Ltd. 





11.12 WuXi Apptec 





List of Figures 

FIG. 1 Active Pharmaceutical Ingredients Market Segmentation 

FIG. 2 Comparative Analysis: Global API Market Revenue, by Geography, 2013 &2020 (Value %) 

FIG. 3 Global API Market Revenue, by Therapeutic Area, 2013 (USD Million) 

FIG. 4 Number of DMF Type II applications filed at the U.S. FDA by countries till 2011 

FIG. 5 Global Active Pharmaceutical Ingredient Market: Value Chain Analysis 


17



FIG. 6 Porter’s Five Forces Analysis: Global Active Pharmaceutical Ingredients Market 

FIG. 7 Market Attractiveness Analysis: Global API Market, by Geography 

FIG. 8 Global Captive or In-house API Manufacturing Market Revenue, 2012 – 2020 (USD Million) 

FIG. 9 Global API Contract Manufacturing Market Revenue, 2012 – 2020 (USD Million) 

FIG. 10 Global Synthetic Chemical API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 11 Top 10 drugs – Small Molecule vs. Biological, by API Type, 2008 and 2013 

FIG. 12 Global Biological API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 13 Global Branded or Innovative Prescription Drugs API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 14 Global Generic Prescription Drugs API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 15 Global Over-the-counter (OTC) Drugs API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 16 Global NSAIDs API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 17 Global Oncology Drugs API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 18 Global Anti-diabetic Drugs API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 19 Global Cardiovascular Drugs API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 20 Global CNS Drugs API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 21 Global Musculoskeletal Drugs API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 22 Global Other Drugs API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 23 North America API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 24 Europe API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 25 Asia Pacific API Market Revenue, 2012 – 2020 (USD Million) 


18



FIG. 26 Rest of the World API Market Revenue, 2012 – 2020 (USD Million) 

FIG. 27 North America Paracetamol (APAP) Market Revenue, 2012 – 2020 (USD Million) 

FIG. 28 North America Paracetamol (APAP) Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 29 Europe Paracetamol (APAP) Market Revenue, 2012 – 2020 (USD Million) 

FIG. 30 Europe Paracetamol (APAP) Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 31 Asia Pacific Paracetamol (APAP) Market Revenue, 2012 – 2020 (USD Million) 

FIG. 32 Asia Pacific Paracetamol (APAP) Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 33 Rest of the World Paracetamol (APAP) Market Revenue, 2012 – 2020 (USD Million) 

FIG. 34 Rest of the World Paracetamol (APAP) Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 35 North America Ibuprofen Market Revenue, 2012 – 2020 (USD Million) 

FIG. 36 North America Ibuprofen Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 37 Europe Ibuprofen Market Revenue, 2012 – 2020 (USD Million) 

FIG. 38 Europe Ibuprofen Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 39 Asia Pacific Ibuprofen Market Revenue, 2012 – 2020 (USD Million) 

FIG. 40 Asia Pacific Ibuprofen Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 41 Rest of the World Ibuprofen Market Revenue, 2012 – 2020 (USD Million) 

FIG. 42 Rest of the World Ibuprofen Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 43 North America Aspirin Market Revenue, 2012 – 2020 (USD Million) 

FIG. 44 North America Aspirin Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 45 Europe Aspirin Market Revenue, 2012 – 2020 (USD Million) 


19



FIG. 46 Europe Aspirin Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 47 Asia Pacific Aspirin Market Revenue, 2012 – 2020 (USD Million) 

FIG. 48 Asia Pacific Aspirin Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 49 Rest of the World Aspirin Market Revenue, 2012 – 2020 (USD Million) 

FIG. 50 Rest of the World Aspirin Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 51 North America Naproxen Market Revenue, 2012 – 2020 (USD Million) 

FIG. 52 North America Naproxen Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 53 Europe Naproxen Market Revenue, 2012 – 2020 (USD Million) 

FIG. 54 Europe Naproxen Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 55 Asia Pacific Naproxen Market Revenue, 2012 – 2020 (USD Million) 

FIG. 56 Asia Pacific Naproxen Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 57 Rest of the World Naproxen Market Revenue, 2012 – 2020 (USD Million) 

FIG. 58 Rest of the World Naproxen Market Volume, 2012 – 2020 (Metric Tons) 

FIG. 59 Actavis plc: Annual Sales Revenue, 2011 – 2013 (USD Million) 

FIG. 60 BASF SE : Annual Sales Revenue of Chemicals, 2012 – 2014 (USD Million) 

FIG. 61 Boehringer Ingelheim: Annual Sales Revenue, 2011 – 2013 (USD Million) 

FIG. 62 Cambrex Corporation: Annual Sales Revenue, 2012 – 2014 (USD Million) 

FIG. 63 Dr. Reddy's Laboratories Ltd.: Annual Sales Revenue, 2012 – 2014 (USD Million) 

FIG. 64 Hospira, Inc.: Annual Sales Revenue, 2011 – 2013 (USD million) 

FIG. 65 Lonza Group: Annual Sales Revenue, 2011– 2013 (USD Million) 


20



FIG. 66 Mylan, Inc.: Annual Sales Revenue, 2011 – 2013 (USD Million) 

FIG. 67 Novartis International AG: Annual Sales Revenue, 2011 – 2013 (USD Million) 

FIG. 68 Pfizer, Inc.: Annual Sales Revenue, 2011 – 2013 (USD Million) 

FIG. 69 Teva, Inc.: Annual Sales Revenue, 2011 – 2013 (USD Million) 

FIG. 70 WuXi PharmaTech (Cayman), Inc.: Annual Sales Revenue, 2011 – 2013 (USD Million) 

List of Tables 

TABLE 1 List of Abbreviations 

TABLE 2 Market Snapshot: Global API Market (2013 & 2020) 

TABLE 3 Patent Expiry of Major Pharmaceutical Drugs, 2009 - 2014 

TABLE 4 Patent Expiry of Major Biological Drugs in the U.S. and EU 

TABLE 5 Event Impact Analysis: Global API Market 

TABLE 6 Competitive Landscape: Global API Market, 2013 (USD Million) 

TABLE 7 Global Active Pharmaceutical Ingredients Market, by Type of Manufacturers, 2012 – 2020 (USD 

Million) 

TABLE 8 Differences between Small Molecule APIs and Biological APIs 

TABLE 9 Global Active Pharmaceutical Ingredients Market, by Therapeutic Area, 2012 – 2020 (USD Million) 

TABLE 10 Global Active Pharmaceutical Ingredients Market, by Geography, 2012 – 2020 (USD Million) 

TABLE 11 Actavis plc: Expenses & Revenue, 2011 – 2013 (USD Million) 

TABLE 12 BASF SE: Expenses & Revenue, 2012 – 2014 (USD Million) 


21



TABLE 13 Cambrex Corporation: Expenses & Revenue, 2011 – 2013 (USD Million) 

TABLE 14 Dr. Reddy's Laboratories Ltd: Expenses & Revenue, 2012 – 2014 (USD Million) 

TABLE 15 Hospira, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million) 

TABLE 16 Mylan, Inc..: Expenses & Revenue, 2011 – 2013 (USD Million) 

TABLE 17 Novartis International AG: Expenses & Revenue, 2011 – 2013 (USD Million) 

TABLE 18 Pfizer, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million) 

TABLE 19 Teva, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million) 

TABLE 20 WuXi PharmaTech, (Cayman), Inc.: Expenses & Revenue, 2011 – 2013 (Thousand USD) 

Browse All Pharmaceutical Market Research Reports @ 

http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html 

About Us 

Transparency Market Research is a market intelligence company providing global business information 

reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking 

insight for thousands of decision makers. 

We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use 

proprietary data sources and various tools and techniques to gather, and analyze information. Our 

business offerings represent the latest and the most reliable information indispensable for businesses to 

sustain a competitive edge. 

Contact 


22




90 State Street, 

Suite 700, 

Albany 

NY - 12207 

United States 

Tel: +1-518-618-1030 

USA - Canada Toll Free 866-552-3453 

Email: sales@transparencymarketresearch.com 

Website: http://www.transparencymarketresearch.com/ 

Browse The Market Research Blog : 

http://researchandreports.wordpress.com/ http://www.transparencymarketresearch.com 


23

Active Pharmaceutical Ingredients (API) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020

Create successful ePaper yourself

Delete template?

Save as template?